PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production
Authors
Keywords
-
Journal
FASEB JOURNAL
Volume 31, Issue 4, Pages 1756-1766
Publisher
FASEB
Online
2017-01-18
DOI
10.1096/fj.201601147r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guillain-Barré syndrome
- (2016) Hugh J Willison et al. LANCET
- Are Th17 cells and their cytokines a therapeutic target in Guillain–Barré syndrome?
- (2015) Xiujuan Wu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells
- (2015) Hiroaki Kimura et al. Journal of Immunology Research
- Coactivator MYST1 Regulates Nuclear Factor-κB and Androgen Receptor Functions During Proliferation of Prostate Cancer Cells
- (2014) Anbalagan Jaganathan et al. MOLECULAR ENDOCRINOLOGY
- Mitigated Tregs and Augmented Th17 Cells and Cytokines are Associated with Severity of Experimental Autoimmune Neuritis
- (2014) X. Wang et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Assembly of the 20S proteasome
- (2013) Mary J. Kunjappu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Th1/Th2/Th17/Treg cytokines in Guillain–Barré syndrome and experimental autoimmune neuritis
- (2013) Hong-Liang Zhang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Glatiramer acetate ameliorates experimental autoimmune neuritis
- (2013) Cun-Jin Zhang et al. IMMUNOLOGY AND CELL BIOLOGY
- Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS)
- (2013) Pieter A. van Doorn PRESSE MEDICALE
- Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
- (2012) Eva M. Huber et al. CELL
- Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice
- (2012) Y. Nagayama et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The immunoproteasome in antigen processing and other immunological functions
- (2012) Michael Basler et al. CURRENT OPINION IN IMMUNOLOGY
- Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain–Barré syndrome
- (2012) Song-lan Liang et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation
- (2012) K. W. Kalim et al. JOURNAL OF IMMUNOLOGY
- How does adaptation sweep through the genome? Insights from long-term selection experiments
- (2012) M. K. Burke PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
- (2011) H. Travis Ichikawa et al. ARTHRITIS AND RHEUMATISM
- Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice
- (2010) Jacqueline Moebius et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
- (2010) M. Basler et al. JOURNAL OF IMMUNOLOGY
- The role of cytokines in Guillain–Barré syndrome
- (2010) Ming-Ou Lu et al. JOURNAL OF NEUROLOGY
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
- (2009) Tony Muchamuel et al. NATURE MEDICINE
- FTY720 attenuates lesional interleukin-17+cell accumulation in rat experimental autoimmune neuritis
- (2009) Z-Y. Zhang et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
- (2008) Deborah J. Kuhn et al. BLOOD
- Bortezomib in the front-line treatment of multiple myeloma
- (2008) Paul G Richardson et al. Expert Review of Anticancer Therapy
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started